What is Mineralys Therapeutics Earnings Power Value (EPV)?
As of Mar24, Mineralys Therapeutics's earnings power value is $7.54. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Mineralys Therapeutics Earnings Power Value (EPV) Historical Data
The historical data trend for Mineralys Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mineralys Therapeutics Earnings Power Value (EPV) Chart
|
Mineralys Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
|
Mineralys Therapeutics Quarterly Data
|
|
Dec20 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Mineralys Therapeutics's Earnings Power Value (EPV)
For the Biotechnology subindustry, Mineralys Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mineralys Therapeutics's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Mineralys Therapeutics's Earnings Power Value (EPV) falls into.
Mineralys Therapeutics Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Mineralys Therapeutics (Mineralys Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Executives
| Jon Congleton |
director, officer: Chief Executive Officer |
3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301 |
| Glenn Sblendorio |
director |
3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036 |
| Daphne Karydas |
director |
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
| David Malcom Rodman |
officer: Chief Medical Officer |
3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301 |
| Ra Capital Healthcare Fund Lp |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Srinivas Akkaraju |
director, 10 percent owner |
565 EVERETT AVENUE, PALO ALTO CA 94301 |
| Hbm Healthcare Investments (cayman) Ltd. |
10 percent owner |
GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,, PO BOX 30852, GRAND CAYMAN E9 KY1-1204 |
| Adam Scott Levy |
officer: CFO, Chief Bus. Off. and Secy. |
C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301 |
| Catalys Pacific Fund, Lp |
10 percent owner |
301 9-19 HACHIYAMA, SHIBUYA, TOKYO M0 150-0035 |
| Olivier Litzka |
director |
C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087 |
| Takeshi Takahashi |
director |
C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087 |
| Brian Taylor Slingsby |
director, 10 percent owner |
C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087 |
| Ra Capital Nexus Fund Iii, L.p. |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Samsara Biocapital, L.p. |
10 percent owner |
628 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
| Alexander Asam |
director |
C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Mineralys Therapeutics (Mineralys Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MLYS has been successfully added to your